Contact Us

We are committed to the professional and patient communities we serve. In the spirit of this commitment, we invite ongoing feedback and dialogue.

Corporate Information:
Lantheus
331 Treble Cove Rd.
N. Billerica, MA 01862
Call Toll-Free: 1.800.362.26681.800.362.2668

US Customer Service/Order DEFINITY®:
Monday-Friday 7:30 AM to 6:00 PM ET
Call Toll-Free: 1.800.299.34311.800.299.3431
Fax: 1.978.671.8860
Fax Orders/POs: 1.978.436.7501

DEFINITY® Reimbursement Support:

Call Toll-Free: 1.800.362.26681.800.362.2668
Press Option 3 for Reimbursement Regarding DEFINITY®
Email: reimbursement@lantheus.com

Lantheus cannot guarantee coverage or payment for products or procedures. Payer policies can vary widely and third-party payment for medical products and services is affected by numerous factors. It is always the provider's responsibility to determine and submit appropriate codes, charges, and modifiers for services rendered. For more specific information, contact your third-party payer directly in order to obtain up-to-date coverage, coding, and payment information.

Adverse Event and Product Quality Complaint Reports:

United States:
Call Toll-Free: 1.800.343.78511.800.343.7851
Press Option 2 for Adverse Events
Press Option 2 for Product Quality Complaints
Fax: 1.978.436.7296
Email: lantheussafety@lantheus.com

Outside the US:
Call Toll-Free: 1.978.667.95311.978.667.9531
Press Option 2 for Adverse Events
Press Option 2 for Product Quality Complaints
Fax: 1.978.436.7296
Email: lantheussafety@lantheus.com

Sales

If you would like a sales representative to contact you, please complete the form below.

Fields marked * are required.

First Name

Last Name

Specialty

Role

NPI Number

Facility

ZIP

Telephone Number

Email Address

Other Specialty

Other Role

*I am interested in the following (check all that apply):

Contact with a sales representative

Product ordering information/customer service ordering information/customer service

Product information, patient education materials

Reimbursement information

Submission of Case Studies

Other

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

How we will use this information:

Lantheus Medical Imaging may collect data from you that you provide to us voluntarily, such as your name, postal address, email address, telephone number, and other personal information, such as your education level, professional affiliation, marital status, or personal medical information. If you provide us with these data, you agree that we may contact you to provide you with information we believe may be of interest to you.

Your information may be provided to other parties that Lantheus Medical Imaging is working with in order to help develop programs and provide services that may be of interest to you or for processing, mailing, and/or Internet-based delivery purposes. Within Lantheus Medical Imaging, data may be transferred to or accessed by authorized Lantheus Medical Imaging personnel in other countries.

If at any time you do not wish to be contacted by Lantheus Medical Imaging, or if you have any questions concerning our privacy practices, please feel free to contact us at bi.webadmin@lantheus.com.

Thank you for subscribing. We look forward to sharing exciting news about DEFINITY®.

INDICATIONS

DEFINITY® is indicated, after activation, for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration.

Assess all patients for the presence of any condition that precludes DEFINITY® administration [see Contraindications (4)].
Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension

INDICATIONS

CONTRAINDICATIONS

DEFINITY® is contraindicated in patients with known or suspected hypersensitivity to perflutren lipid microsphere or its components, such as polyethylene glycol (PEG) [see Warnings and Precautions (5.2) and Description (11)].

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Assess all patients for the presence of any condition that precludes DEFINITY® administration [see Contraindications (4)].
Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

In postmarketing use, rare but serious cardiopulmonary or hypersensitivity reactions have been reported during or shortly following perflutren and PEG-containing microsphere administration [see Adverse Reactions (6)]. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions and/or with pre-existing PEG hypersensitivity [see Adverse Reactions (6.2)]. It is not always possible to reliably establish a causal relationship to drug exposure due to the presence of underlying conditions.

Patients with sickle cell disease may be at higher risk of painful crisis and DEFINITY® should be administered with caution.

Please see accompanying full Prescribing Information, including boxed WARNING regarding serious cardiopulmonary reactions.

Customer Service 1.800.299.3431

BACK TO
TOP